Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX10 + Chemotherapy in Previously Untreated Japanese Patients With ES-SCLC
NCT06812260Phase 2Active, not recruiting
- Sponsor
- Henlius
- Start
- Jun 2025
- Primary completion
- Oct 2026
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of serplulimab in small cell lung cancer (SCLC), sponsored by Henlius. Primary endpoint: Response (CR or PR) rate at 24 weeks. Started Jun 2025; status: active, not recruiting.
02
Drugs
serplulimab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT06812260.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06812260.